Article Information
- Received November 26, 2023
- Revision received March 27, 2024
- Accepted April 5, 2024
- Published online April 11, 2024.
Author Information
- Yuri Hirayama1,
- Ha Pham Ngoc Le2,
- Hirofumi Hashimoto1,
- Itsuko Ishii3,
- Schuichi Koizumi2,4 and
- Naohiko Anzai1
- 1Department of Pharmacology, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan
- 2Department of Neuropharmacology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Yamanashi 409-3898, Japan
- 3Division of Pharmacy, Chiba University Hospital, Chiba 260-8677, Japan
- 4GLIA Center, University of Yamanashi, Yamanashi 409-3898, Japan
- Correspondence should be addressed to Yuri Hirayama at yhirayama{at}chiba-u.jp or Naohiko Anzai at afga5078{at}faculty.gs.chiba-u.jp.
Author contributions
Author contributions: Y.H., S.K., and N.A. designed research; Y.H. and H.P.N.L. performed research; Y.H., H.H., I.I., S.K., and N.A. analyzed data; Y.H. wrote the paper.
Disclosures
The authors declare no competing financial interests.
Grant sponsors: This study was supported by Japan Society for the Promotion of Science Kakenhi 22K06853 (Y.H.), 20H05902 (S.K.), 21H04786 (S.K.), and 21K19309 (S.K.); the Uehara Memorial Foundation (Y.H.); the Astellas Foundation for Research on Metabolic Disorders (Y.H.); and The Naito Foundation (Y.H.). We thank the members of the Anzai and Koizumi labs for their helpful comments and discussion. We also thank Drs. Enaida (Saga University) and Notomi (Kyushu University) for providing the P2X7 receptor knock-out mice. We thank Bronwen Gardner, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.
Funding
JSPS KAKENHI
22K06853; 20H05902; 21H04786; 21K19309Uehara Memorial Foundation (UMF)
Astellas Foundation for Research on Metabolic Disorders
Naito Foundation (内藤記念科学振興財団)
Other Version
- You are viewing the most recent version of this article.
- previous version (April 11, 2024).
Article usage
In this issue
